| Project/Area Number |
26460164
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Hyogo University of Health Sciences |
|---|
Principal Investigator |
TANAKA AKITO 兵庫医療大学, 薬学部, 教授 (30454789)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TSUJIKAWA KAZUTAKE 大阪大学, 薬学研究科, 教授 (10207376)
|
|---|
| Research Collaborator |
TOKORO MIYUKI (MABUCHI MIYUKI) 兵庫医療大学, 薬学部, 研究員 (60714897)
INOUE TAKASHI 大阪大学, 工学研究科, 教授 (20263204)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 抗がん剤 / PCA-1 / 創薬化学 / 前立腺癌 / 代謝安定性 / xenograftモデル / 経口剤 / PCA-1阻害剤 / 前立腺がん |
|---|
| Outline of Final Research Achievements |
We designed and synthesized novel PCA-1 inhibitors to obtain clinical effective novel anticancer drugs. Oral administration of HUHS015, a representative compound, showed the effectiveness in a DU145 Xenograft model withoutside effects, which demonstrated the effectiveness of PCA-1 inhibitor as anti-cancer drugs.
|
